About Fusidic Acid 2% + Mometasone Furoate 0.1% Cream — Dual-Action Formulation for Infected Inflammatory Dermatoses
Fusidic Acid 2% + Mometasone Furoate 0.1% Cream is a fixed-dose combination topical dermatological formulation that addresses two simultaneous pathological drivers of infected skin conditions — bacterial proliferation and inflammatory cascade activation — through complementary mechanisms within a single cream application.
Fusidic Acid 2.0% w/w — Broad-Spectrum Topical Antibiotic
Fusidic acid is a steroidal antibiotic belonging to the fusidane class, with potent bacteriostatic and bactericidal activity primarily against gram-positive organisms — most critically Staphylococcus aureus, including methicillin-sensitive strains that are the predominant causative pathogens in primary and secondary bacterial skin infections. Its mechanism centers on inhibiting bacterial protein elongation factor G (EF-G), blocking translocation on the ribosome and thereby halting bacterial protein synthesis at the translocation step. This targeted mechanism is structurally distinct from beta-lactam and macrolide antibiotics, making fusidic acid effective even in patients with penicillin sensitivity. At 2% topical concentration, it achieves therapeutically significant tissue levels in the epidermis and dermis while maintaining a low systemic absorption profile — critical for the dermatology prescribing community's safety considerations.
Mometasone Furoate 0.1% w/w — Potent Class III Topical Corticosteroid
Mometasone furoate is a synthetic fluorinated corticosteroid classified as a moderately potent (Class III) topical steroid with an exceptionally high receptor-binding affinity relative to its systemic absorption. It suppresses the entire inflammatory cascade — inhibiting phospholipase A2, reducing prostaglandin and leukotriene synthesis, downregulating pro-inflammatory cytokine release, and reducing mast cell and eosinophil recruitment. Clinically this translates to rapid resolution of the erythema, oedema, pruritus, and weeping characteristic of inflamed, infected dermatoses. Mometasone's low skin atrophy potential compared to higher-potency steroids (such as clobetasol propionate) makes it a well-tolerated choice in combination formulations for conditions requiring antibiotic co-therapy.
Synergistic Clinical Rationale
The combination directly addresses why either agent alone often under-delivers in infected inflammatory dermatoses: the antibiotic eliminates the infection driver while the corticosteroid resolves the inflammatory response that perpetuates symptoms and delays healing. For fusidic acid mometasone furoate cream manufacturers and pharma brands developing a premium dermatology portfolio, this combination represents a high-prescription-volume, therapeutically validated topical that commands strong prescriber loyalty across dermatology and general practice settings in India and export markets.
Therapeutic Indications — What Fusidic Acid and Mometasone Cream Treats
The clinical applications of fusidic acid and mometasone furoate cream span the full spectrum of infected inflammatory dermatoses — conditions where concurrent bacterial infection and cutaneous inflammation demand simultaneous therapeutic targeting.
Primary Dermatological Indications
Infected Eczema (Eczema with Secondary Bacterial Infection)
This is the most prevalent indication for fusidic acid and mometasone combination cream. Atopic eczema and contact dermatitis frequently become secondarily infected with Staphylococcus aureus — a scenario where monotherapy with either a steroid or an antibiotic alone produces incomplete clinical resolution. The combination simultaneously clears the bacterial superinfection while resolving the inflammatory flare, producing faster symptomatic relief and more durable outcomes than sequential monotherapy. For dermatology-focused pharma brands, infected eczema cream represents a high-volume prescription category with consistent repeat prescription rates.
Infected Atopic Dermatitis
Atopic dermatitis patients carry significantly elevated cutaneous Staphylococcus aureus colonisation, and acute flares are frequently precipitated or worsened by bacterial infection. Fusidic acid's targeted anti-staphylococcal activity combined with mometasone's anti-inflammatory potency makes this combination a first-line choice in dermatologist prescribing for infected atopic dermatitis episodes.
Bacterial Dermatitis & Secondary Infected Dermatoses
Contact dermatitis, seborrhoeic dermatitis, and other eczematous dermatoses that develop secondary bacterial infection respond well to this combination — particularly where the bacterial component involves Staphylococcus or Streptococcus species and where inflammation is the predominant patient complaint alongside infection.
Impetigo (Primary Bacterial Skin Infection)
In impetigo — a highly contagious primary bacterial skin infection predominantly caused by Staphylococcus aureus and Streptococcus pyogenes — the combination provides direct antibacterial action via fusidic acid while mometasone addresses the associated inflammatory response and pruritus, improving both healing rate and patient comfort.
Folliculitis
Bacterial folliculitis, involving superficial infection of hair follicles with associated perilesional inflammation and erythema, responds effectively to topical fusidic acid's bactericidal action. The corticosteroid component simultaneously suppresses the inflammatory response responsible for the characteristic perifollicular redness and swelling.
Infected Inflammatory Skin Conditions (Infected Dermatoses)
Beyond specific diagnoses, this cream addresses a broad category of infected inflammatory skin conditions in which chronic or acute inflammation has created a compromised skin barrier susceptible to bacterial colonisation and infection — a very common presentation in dermatology clinical practice requiring combination antibiotic-steroid topical therapy.
cGMP Manufacturing Infrastructure — Topical Antibiotic-Corticosteroid Cream Production
Manufacturing fusidic acid 2% + mometasone furoate 0.1% cream requires precise formulation expertise that goes significantly beyond standard single-agent cream production. The formulation demands careful API compatibility management — ensuring chemical stability between the steroidal antibiotic (fusidic acid) and the corticosteroid (mometasone furoate) within the same emulsion matrix, across the product's entire shelf life.
Delwis Healthcare's semi-solid topical manufacturing facility is specifically equipped for the technical demands of combination antibiotic-corticosteroid cream manufacturing:
- Precision emulsification systems maintaining exact water-in-oil or oil-in-water emulsion phase ratios for consistent API dispersion and cream texture batch-to-batch
- pH-controlled blending ensuring formulation stability within the specific pH window required for both fusidic acid and mometasone furoate to remain chemically stable and therapeutically active
- Controlled-temperature homogenization preventing thermal degradation of mometasone furoate during high-shear mixing — a critical manufacturing step for corticosteroid cream stability
- Dedicated dermatology production lines preventing cross-contamination with other therapeutic categories and ensuring the quality integrity of every batch
- ISO-classified cleanroom environments for filling and packaging, meeting microbiological standards for topical semi-solid pharmaceutical products
- In-process controls including real-time viscosity monitoring, pH verification, and appearance checks at each production stage
This manufacturing precision translates directly into batch-to-batch consistency, reliable potency, and the formulation stability that pharmaceutical brands require when sourcing a fusidic acid mometasone cream manufacturer in India.
Third Party & Contract Manufacturing — Fusidic Acid Mometasone Furoate Cream for Pharma Brands
Delwis Healthcare operates as a dedicated third party pharmaceutical manufacturer and CDMO partner for fusidic acid 2% + mometasone furoate 0.1% cream — providing complete manufacturing solutions for pharmaceutical companies, dermatology brands, and healthcare distributors targeting India's dermatology segment and export markets.
Our Manufacturing Partnership Models
Third Party Manufacturing
Manufacture fusidic acid and mometasone furoate cream under your own pharmaceutical brand with full GMP-compliant production support — from API sourcing and formulation processing through quality testing, tube filling, labeling, and carton packing. Zero infrastructure investment required from your side. Ideal for established pharma companies expanding their dermatology product range or adding a new antibiotic-steroid combination cream SKU.
Contract Manufacturing (CDMO)
End-to-end contract development and manufacturing — encompassing formulation stability work, API compatibility profiling, scale-up from pilot to commercial batch, full quality release testing, stability study execution, and regulatory documentation preparation. Our CDMO model is purpose-built for pharmaceutical brands that require a long-term, technically capable, and compliance-assured manufacturing partner for their infected skin cream range.
Private Label Manufacturing
Launch a fully branded fusidic acid mometasone cream under your label — with custom tube design, carton artwork, batch coding, and packaging specifications aligned with your target market's regulatory and branding requirements. Available for domestic Indian market and export buyers.
Custom Formulation Development
Our formulation R&D team can modify excipient profiles, adjust emollient and humectant levels, develop ointment base variants, or create enhanced skin penetration formulations — offering differentiated product variants for specific prescriber preferences or export market regulatory requirements.
Bulk Contract Supply
High-volume, consistent batch supply for institutional procurement, government tenders, hospital formularies, and export distribution partners — with complete batch documentation, COA, and supply chain reliability.
Pharmaceutical companies looking for a steroid antibiotic cream manufacturer in India or a dermatology cream CDMO partner in Gujarat will find Delwis Healthcare fully equipped, certified, and operationally ready to support their product launch and scaling requirements.
Packaging Specifications — Fusidic Acid Mometasone Furoate Cream
Fusidic Acid 2% + Mometasone Furoate 0.1% Cream is manufactured and supplied in a 10 gm laminated tube — the pharmaceutical standard for topical combination dermatology creams:
- Laminated aluminium tube construction providing a complete barrier against moisture ingress, light exposure, and oxygen permeation — critical for preserving both the antibiotic potency of fusidic acid and the corticosteroid stability of mometasone furoate throughout the product shelf life
- Tamper-evident sealed tube ensuring product integrity from manufacturing to patient use
- Validated shelf life of 24 months under recommended storage conditions (store below 30°C in a cool, dry place, away from direct sunlight and moisture)
- Secondary carton with full prescribing information, batch details, and regulatory labeling
Custom packaging formats — including 15 gm, 20 gm, and 30 gm tubes, alternate tube materials, institutional bulk packaging, and fully customized carton branding — are available for third party manufacturing and private label buyers targeting specific domestic or export market segments.
Quality Assurance — WHO-GMP Compliant Fusidic Acid Mometasone Cream Manufacturing
Every production batch of Fusidic Acid 2% + Mometasone Furoate 0.1% Cream manufactured at Delwis Healthcare is subjected to a rigorous, multi-parameter quality control and release protocol:
- HPLC Analysis — Independent quantification of both fusidic acid and mometasone furoate content per batch against validated pharmacopoeial reference standards
- API Compatibility Testing — Chemical compatibility verification between fusidic acid and mometasone furoate within the cream matrix across time points
- pH Testing — Batch-level pH verification confirming formulation remains within the validated skin-compatible and API-stable pH range
- Viscosity & Spreadability — Confirms consistent semi-solid texture and uniform application performance across production batches
- Microbial Limit Testing — Full microbiological assessment ensuring absence of specified organisms and total microbial count compliance for topical use
- Preservative Efficacy Testing — Validates the antimicrobial preservative system's effectiveness across the product shelf life
- Stability Studies — ICH-compliant real-time and accelerated stability data generated for regulatory submission support (DCGI, export market regulatory filings)
- Raw Material Release — Both fusidic acid API and mometasone furoate API are tested and released against specification before production commencement
Quality Management System aligned with WHO-GMP, USP, BP, and IP pharmacopoeial standards — with complete batch traceability and regulatory documentation maintained for every production run.
Why Dermatology Brands Choose Delwis Healthcare for Fusidic Acid Mometasone Cream Manufacturing
Pharmaceutical companies and dermatology brands select Delwis Healthcare as their contract manufacturing and third party partner for fusidic acid and mometasone furoate cream because of:
- WHO-GMP & ISO 9001 Certified Manufacturing — Compliance infrastructure accepted for domestic Indian market and international export regulatory submissions
- Combination Dermatology Cream Expertise — Proven capability in antibiotic-corticosteroid combination topical formulations requiring API compatibility management and precise stability control
- End-to-End CDMO Services — From formulation development and pilot batching through commercial scale-up, stability studies, and regulatory documentation
- Flexible Production Scale — Scalable from development and stability batches to high-volume commercial production without quality compromise
- Private Label Ready — Complete custom branding, tube design, and carton artwork support for domestic and export market product launches
- Regulatory Documentation Support — Stability data, batch analysis reports, COA, and compliance documentation available for DCGI and international market regulatory filings
- Competitive Manufacturing Cost — Cost-efficient production from Gujarat, India with no compromise on pharmacopoeial quality standards
- Dedicated Dermatology Portfolio — Deep formulation and manufacturing expertise across the full spectrum of topical dermatology products — creams, ointments, gels, and lotions
Frequently Asked Questions — Fusidic Acid & Mometasone Furoate Cream Manufacturing
Q1: Are you a third party manufacturer of Fusidic Acid 2% + Mometasone Furoate 0.1% Cream?
Yes. Delwis Healthcare is a WHO-GMP certified third party pharmaceutical manufacturer and CDMO partner offering complete contract manufacturing of fusidic acid 2% + mometasone furoate 0.1% cream in India — including formulation production, quality control, tube filling, private labeling, and regulatory documentation support for domestic and export market pharma brands and dermatology companies.
Q2: What is Fusidic Acid and Mometasone Cream used for?
Fusidic acid and mometasone cream is clinically indicated for infected inflammatory dermatoses — conditions where bacterial skin infection and cutaneous inflammation coexist and require simultaneous treatment. Primary indications include infected eczema, secondary-infected atopic dermatitis, infected contact dermatitis, impetigo, folliculitis, and other infected inflammatory skin conditions caused predominantly by Staphylococcus aureus. Fusidic acid eliminates the bacterial infection while mometasone furoate resolves the associated inflammation, erythema, and pruritus.
Q3: How does Fusidic Acid work in this combination?
Fusidic acid inhibits bacterial protein synthesis by blocking elongation factor G (EF-G) on the bacterial ribosome — preventing translocation and thereby halting bacterial replication. Its mechanism is structurally distinct from most other antibiotic classes, giving it efficacy against gram-positive pathogens including Staphylococcus aureus without cross-resistance with beta-lactam or macrolide antibiotics. At 2% topical concentration, it achieves effective tissue levels in infected skin while maintaining a low systemic absorption profile.
Q4: What is the role of Mometasone Furoate in this cream?
Mometasone furoate at 0.1% w/w is a Class III potent topical corticosteroid that suppresses the inflammatory response — reducing prostaglandin and cytokine release, controlling mast cell activity, and resolving the erythema, oedema, pruritus, and weeping associated with infected inflammatory skin conditions. Its relatively lower skin atrophy risk compared to higher-potency steroids makes it well-suited for combination use in infected dermatoses requiring antibiotic co-therapy.
Q5: Can this cream be manufactured in custom pack sizes or as an ointment variant?
Yes. As a full-service CDMO and contract manufacturer, Delwis Healthcare supports custom tube sizes (10 gm, 15 gm, 20 gm, 30 gm), formulation variant development (cream to ointment base), excipient profile modifications, and fully customized secondary packaging and branding — available for both domestic Indian market and export market third party manufacturing buyers.
Q6: What certifications does your manufacturing facility hold for dermatology cream production?
Our facility is certified under WHO-GMP, ISO 9001, and ISO 14001. Manufacturing processes for topical semi-solid formulations are validated in compliance with USP, BP, and IP pharmacopoeial standards. Complete batch manufacturing records, stability data, and compliance documentation are maintained for domestic and international regulatory submissions.
Q7: What is the difference between Fusidic Acid and other topical antibiotics like Mupirocin?
Fusidic acid and mupirocin are both commonly used topical antibiotics with strong anti-staphylococcal activity, but their mechanisms differ. Fusidic acid inhibits elongation factor G, while mupirocin inhibits isoleucyl-tRNA synthetase. For combination formulation purposes, fusidic acid is the preferred pairing with corticosteroids in infected eczema and dermatitis because of its established stability profile in cream bases and its long clinical track record in infected inflammatory dermatoses across dermatology practice.
Q8: What is the shelf life of Fusidic Acid 2% + Mometasone Furoate 0.1% Cream?
Our fusidic acid mometasone furoate cream carries a validated shelf life of 24 months under recommended storage conditions — below 30°C, in a cool dry environment, protected from direct light and humidity. The laminated aluminium tube provides the moisture and light barrier protection essential for maintaining both API stabilities throughout this shelf life.
Q9: Do you provide stability and regulatory documentation for export markets?
Yes. Real-time and ICH-compliant accelerated stability studies, certificates of analysis, batch manufacturing records, and full regulatory compliance documentation are available — supporting DCGI licensing submissions, WHO prequalification applications, and export market regulatory filings across Southeast Asia, Africa, the Middle East, and other regulated and semi-regulated markets.
Q10: What is the minimum order quantity for third party manufacturing of this cream?
MOQ is flexible and determined based on batch size, formulation specifications, and the buyer's market volume requirements. Contact our team at info@delwishealthcare.com or call +91 9904405470 to discuss your specific requirements and receive a customized manufacturing quote.
